Evonik Industries AG: Evonik expands lipid-based drug delivery capabilities with new GMP manufacturing facility in Vancouver
Kort samengevat
New GMP (good manufacturing practice) facility to meet increasing demand for lipid nanoparticle (LNP) development and clinical drug product manufacturingEvonik invests over 150 million CAD (93
Verder lezen bij de bron
Bekijk het volledige nieuwsbericht rechtstreeks bij FinanzNachrichten.de.
Lees het volledige bericht ↗